Genomic Valley Biotech Ltd
₹ 39.0
-0.31%
12 Sep
- close price
About
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
Key Points
- Market Cap ₹ 11.9 Cr.
- Current Price ₹ 39.0
- High / Low ₹ 108 / 37.1
- Stock P/E 47.6
- Book Value ₹ 12.7
- Dividend Yield 0.00 %
- ROCE 11.8 %
- ROE 9.68 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.06 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Company has high debtors of 960 days.
- Promoter holding has decreased over last 3 years: -21.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.78 | |
| 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.45 | |
| Operating Profit | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.33 |
| OPM % | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 42.31% |
| 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.01 | |
| Interest | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.34 |
| Tax % | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | ||
| 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.25 | |
| EPS in Rs | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 189% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | % |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.85 | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 |
| 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.61 | 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | |
| Total Liabilities | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 |
| 3.02 | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.55 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| 3.24 | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | |
| Total Assets | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.09 | -0.69 | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | |
| 0.01 | -0.65 | 0.53 | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 | 0.07 | -1.55 | -0.70 | 0.00 | 0.00 | |
| Net Cash Flow | 0.01 | -0.56 | -0.16 | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | ||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 |
| Working Capital Days | 7,746.11 | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 |
| ROCE % | 0.41% | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.83% |
Documents
Announcements
-
Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2025, Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015
4 Sep - ROC approved 3-month extension to hold AGM for FY2024-25, now due by 31-Dec-2025 (approval dated 04-Sep-2025)
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Newspaper Advertisement regarding publication of unaudited financial result of the company for the quarter ended 30 June, 2025.
-
Re-Appointment Of Mr. Yogesh Agrawal As Chairman & Managing Director Of The Company For The Period Of Five (5) Years With Effect From 07.09.2025
7 Aug - Q1 FY2025-26 results approved; MD re-appointed for 5 years; new secretarial and internal auditors appointed.
-
Appointment Of Internal Auditor For The FY 2025-26.
7 Aug - Approved Q1 FY25 unaudited results; appointed secretarial, internal auditors; re-appointed MD for 5 years.
-
Appointment Of Secretarial Auditor
7 Aug - Approved Q1 FY25 unaudited results; appointed secretarial and internal auditors; re-appointed MD for 5 years.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2]
GVBL, with its experience in Next-Generation Sequencing (NGS), oncology, and Artificial Intelligence (AI), provides biotechnology
and healthcare solutions. The company provides personalized therapy options, helping doctors with decision-making support and identifying effective treatments, and aims to transform oncology research and diagnostics.
The company also provides Research Process Outsourcing (RPO) services to global researchers